FDA Lowers the Sweet Bar for Pasteurized Orange Juice

2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY

The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.

2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI

The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.

2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS

The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.

2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA

The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.

2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO

The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.

2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER

The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.

Previous: 2025-15461 — Air Plan Approval; GA; Updates to the Cross-State Air Pollution Rule

The EPA is set to approve Georgia’s updated plan to control air pollution from big power plants, making sure it matches federal rules for cutting harmful gases like nitrogen oxides and sulfur dioxide. This update helps Georgia keep the air cleaner for everyone, especially during the ozone season from May to September. Power plants and communities will see clearer rules soon, with no extra costs expected.

Next: 2025-15491 — Endangered and Threatened Wildlife and Plants; Threatened Species Status With Section 4(d) Rule for the Borneo Earless Monitor

The U.S. Fish and Wildlife Service wants to protect the Borneo earless monitor, a rare lizard, by listing it as a threatened species. This means new rules will help keep it safe from harm. If approved, these protections will start soon and could affect how people handle or trade this unique lizard.